Key Takeaways
- NeoGenomics shares fell 12% after the company named President and COO Warren Stone as its next CEO and said third-quarter revenue should be about $209 million, above the $205.9 million consensus.
- The company kept its full-year guidance where it was for now and said the increase will come on its earnings call, and that gave holders of a stock up 62% this year a reason to sell.
- Even after the drop, NeoGenomics trades at about 62x forward earnings, far above its five-year average of about 41x.
- 10x Genomics and Twist Bioscience fell by similar amounts on the same day, and the third-quarter call is where investors will see how big the guidance increase is.
NeoGenomics (NEO) shares fell 12% today after the cancer-testing company announced a CEO handoff and a quarter that beat Wall Street’s revenue estimate.
So, why the drop?
What exactly happened
After Monday’s close, NeoGenomics said:
- President and COO Warren Stone becomes CEO on Jan. 4, 2027.
- CEO Tony Zook stays on through Jan. 3, then becomes Executive Chair.
- Board Chair Lynn Tetrault steps down as Chair the same day.
- Third-quarter revenue should come in around $209 million, above the $205.9 million consensus, with next-generation sequencing (NGS) revenue up about 28%.
Zook described it as a planned handoff: “With our aligned long-term strategy in place and delivering results, this transition emphasizes strategic continuity.”
The beat came without a raise
Here’s the thing: NeoGenomics only repeated the full-year revenue guidance of $802 million to $806 million it set on July 28. It said any increase will come on its earnings call.
Add the $209 million to the first half’s $388 million, and you get about $597 million through September. That means the current guidance implies a fourth quarter no bigger than the third.
Analysts already sit at the midpoint, about $804 million this year, with steady growth after that…
A modest raise would nudge this year’s figure up without changing that path. But why make everyone wait if you’re going to raise guidance? Smells a little risky.
A rich price, and a rough day
And investors were already paying a lot. The stock is up 62% this year, and at Monday’s close it traded at about 70 times forward earnings, according to data from TIKR.com.
Even after Tuesday’s drop, that’s about 62x, far above its five-year average of about 41x.
A leadership change with no guidance increase attached gave holders a reason to sell.
Wall Street liked the news. BTIG upgraded the stock to Buy from Neutral with a $28 price target, and StoneX raised its target to $20 from $16, calling the pre-announcement “positive.”
I read Tuesday’s drop as profit-taking in an expensive stock on a bad day for its sector, while the business stays on track. The third-quarter call will show how big that guidance increase is. Of course, a new CEO can still shift priorities once he takes over in January.
So what is NeoGenomics stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what NeoGenomics could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!
